Whole Exome Sequencing Market Size 2025-2029
The whole exome sequencing market size is forecast to increase by USD 3.7 billion, at a CAGR of 21.1% between 2024 and 2029.
The global whole exome sequencing market is expanding, driven by technological advancements and a steep decline in sequencing costs. This has transitioned WES from a niche research application to a routine tool in clinical diagnostics and genomics. The integration of artificial intelligence and machine learning is a key trend, accelerating variant interpretation and addressing the data bottleneck. This synergy enhances the dna sequencing market by shifting value from sequencing speed to the accuracy of interpretive reports. Such developments in bioinformatics are crucial for managing the large datasets generated and improving the diagnostic yield from genomic tests. The focus on genome engineering is also contributing to the evolution of sequencing applications in clinical practice.Despite these advancements, the market's growth is constrained by the bioinformatics bottleneck and the complexity of data interpretation. The process of identifying clinically significant variants from tens of thousands of possibilities requires specialized expertise and sophisticated computational tools. This analytical hurdle limits the scalability of WES services and impacts their cost-effectiveness. A significant portion of variants identified through WES are of uncertain significance, creating diagnostic ambiguity. The next generation sequencing market is therefore heavily invested in developing advanced analytical tools and promoting carrier screening to overcome these challenges and unlock the full potential of whole exome sequencing in routine healthcare.
What will be the Size of the Whole Exome Sequencing Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The technical foundation of the global whole exome sequencing market continues to advance, with developments in sequencing by synthesis and ion semiconductor sequencing improving throughput and accuracy. Innovations in exome enrichment kits and library preparation kits are crucial for enhancing diagnostic yield. The emergence of long-read sequencing technologies is particularly significant, offering new capabilities to resolve structural variants and copy number variations that are challenging for short-read methods. These advancements in the next generation sequencing market are expanding the scope of both research and clinical applications in genomics.In clinical practice, the application of whole exome sequencing is broadening beyond its initial focus on rare genetic diseases. It is now integral to targeted therapy selection in oncology, where the identification of somatic mutations and germline sequencing informs personalized treatment plans. The field of pharmacogenomics also increasingly relies on WES to predict patient responses to drugs. This expansion into mainstream clinical diagnostic workflows is supported by a growing body of evidence demonstrating its utility. The development of comprehensive sample-to-report solutions is making this technology more accessible to a wider range of healthcare providers undertaking carrier screening.The primary operational challenge remains the complexity of clinical variant interpretation and the associated bioinformatics bottleneck. The use of sophisticated bioinformatics pipelines and machine learning algorithms is essential for managing the large datasets and addressing the issue of variants of uncertain significance. The focus on next generation sequencing data analysis market is therefore critical. Establishing large-scale clinico-genomic databases and federated data networks is a key priority to improve the accuracy of variant classification and support the continued growth of precision medicine initiatives globally.
How is this Whole Exome Sequencing Industry segmented?
The whole exome sequencing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Product
- Consumables
- Services
- Instruments
- Technology
- Sequencing by synthesis
- ION semiconductor sequencing
- Others
- Application
- Drug discovery and development
- Diagnostics
- Personalized medicine
- Prenatal and neonatal screening
- Others
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- The Netherlands
- Spain
- Russia
- Asia
- Rest of World (ROW)
By Product Insights
The consumables segment is estimated to witness significant growth during the forecast period.
The consumables segment represents the financial engine of the whole exome sequencing market, encompassing all recurring materials required for the WES workflow. This includes sample and library preparation kits, exome enrichment kits for targeted capture, and sequencing reagents. The demand for these products is directly tied to the global volume of WES procedures. Innovation is focused on enhancing performance metrics like on-target capture efficiency and coverage uniformity, which improves data quality and workflow efficiency. The quality of these consumables is paramount.
As the exome contains approximately 85% of known disease-causing mutations, the effectiveness of enrichment kits in accurately capturing these regions directly impacts diagnostic success. While platform manufacturers often bundle proprietary reagents, the library preparation and enrichment steps remain a competitive field. For clinical applications, the demand for high-quality, validated consumables is particularly strong, as consistency and reliability are essential for diagnostic accuracy. This segment's growth is fueled by increasing test volumes and continuous product enhancements that drive higher data quality.
Request Free Sample
The Consumables segment was valued at USD 658.10 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 44.0% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
North America holds the largest share of the global whole exome sequencing market, a position supported by its high healthcare expenditure and a robust, well-funded research ecosystem. The United States National Institutes of Health provides substantial funding for genomic research, directly and indirectly supporting the use of whole exome sequencing. This continuous government investment fosters a climate of innovation and sustains demand. The region benefits from a clear regulatory pathway for clinical diagnostics and a high concentration of academic medical centers and biotechnology firms.
A crucial factor in the North American market is the evolving reimbursement landscape, with growing coverage for whole exome sequencing from public and private payers, particularly for rare diseases and oncology. This trend is expanding access and solidifying the technology's clinical utility. The region's leadership in applying artificial intelligence for variant interpretation further strengthens its market position. Driven by expanding clinical applications, North America is projected to capture a substantial portion of the incremental growth, accounting for over 44% of the market's expansion during the forecast period.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global whole exome sequencing market is experiencing robust growth, propelled by significant advancements in next generation sequencing technologies and the proliferation in population health initiatives. Key applications driving adoption include sequencing for rare and undiagnosed diseases and comprehensive genomic profiling for personalized cancer care. Furthermore, the integration into standard diagnostic workflows is becoming more commonplace, supported by large scale government precision medicine initiatives aiming for population scale sequencing for preventive medicine. This trend toward the democratization of genomic information access is further accelerated by innovations like the ascendancy of long read sequencing technologies and the use of artificial intelligence for accelerated variant interpretation, which are pivotal in making complex genomic insights more accessible.Despite this positive trajectory, the market faces considerable challenges that require strategic navigation. The inherent complexity of clinical data interpretation and the difficulty in managing variants of uncertain significance remain significant hurdles. Providers are also grappling with inconsistent reimbursement policies for genomics and the complex ethical legal social implications of WES. On the technical front, efforts are focused on optimizing exome capture efficiency and resolving complex regions of the exome to improve data quality. Concurrently, there is a strong industry push toward reducing turnaround time for diagnostic reports and enhancing diagnostic yield from genomic tests, while ensuring regulatory compliance for in vitro diagnostics and effectively securing large genomic datasets.
What are the key market drivers leading to the rise in the adoption of Whole Exome Sequencing Industry?
- Technological advancements and the precipitous decline in sequencing costs are the foundational drivers expanding the global whole exome sequencing market.
Continuous advancements in next-generation sequencing technologies, paired with a dramatic reduction in costs, are primary drivers of market expansion. This dual force has democratized access to genomic information, transitioning whole exome sequencing from a specialized research tool to a viable clinical diagnostic method. The cost to sequence an exome has fallen at a rate far exceeding Moore's Law, making it economically feasible for a wider range of institutions. This cost erosion lowers the barrier to adoption and improves the return on investment for genomic analysis, especially as the exome represents less than 2% of the total genome. Technological improvements in sequencing accuracy, throughput, and turnaround time further enhance its clinical utility and stimulate demand.The market is also driven by the expanding and validated clinical utility of whole exome sequencing, particularly in diagnostics for rare genetic diseases, oncology, and pharmacogenomics. It offers a superior diagnostic yield compared to traditional single-gene or panel-based tests. For patients with undiagnosed diseases, WES often provides a definitive genetic cause after years of inconclusive testing. This capability has led to its growing integration into standard care, especially in pediatric medicine. The fact that the exome contains approximately 85% of known disease-causing mutations makes it a highly effective and cost-efficient strategy for identifying genetic variations associated with human disease, firmly establishing its role in advancing precision medicine.
What are the market trends shaping the Whole Exome Sequencing Industry?
- The integration of artificial intelligence and machine learning to accelerate variant interpretation is a transformative trend within the market.
The integration of artificial intelligence and machine learning is a important trend, addressing the primary bottleneck in the diagnostic pipeline: variant interpretation. Whole exome sequencing produces vast amounts of data, and identifying clinically significant variants is a complex challenge. Advanced computational systems trained on large genomic and phenotypic datasets can recognize patterns that elude human analysis. These AI-powered tools rapidly sift through thousands of variants, prioritizing them based on predicted pathogenicity and evidence from scientific literature. This automation significantly reduces manual effort, accelerating turnaround times for diagnostic reports and shifting the value proposition from sequencing speed to the accuracy and utility of the final interpretive report in the next generation sequencing data analysis market.A second pivotal trend is the transition of whole exome sequencing from a specialized research tool into a mainstream component of clinical diagnostics and population health programs. This shift is fueled by falling costs, growing evidence of clinical utility, and government-funded precision medicine initiatives. Healthcare systems are adopting a genetics-first approach, using WES for early identification of individuals at high risk for preventable conditions. While some studies show that new technologies can identify pathogenic structural variants in nearly 15% of previously unresolved cases, the core trend is broader clinical integration. There is a growing demand for turnkey, clinically validated sample-to-report solutions that lower the barrier to entry for hospitals, supporting applications like carrier screening and other aspects of genomics.
What challenges does the Whole Exome Sequencing Industry face during its growth?
- The bioinformatics bottleneck and the inherent complexity of data interpretation remain a significant challenge to widespread market adoption.
A formidable challenge for the whole exome sequencing market is the analysis and clinical interpretation of the generated data. This bioinformatics bottleneck impedes the widespread adoption of WES in clinical settings. Sequencing an exome produces a vast amount of raw data containing tens of thousands of genetic variants. The core difficulty is accurately identifying the one or two clinically significant variants responsible for a patient's condition. This process requires a sophisticated multi-step bioinformatics pipeline, substantial computational resources, and highly specialized human expertise. A global shortage of qualified bioinformaticians and clinical geneticists leads to long turnaround times and increases the risk of interpretive errors, constraining the scalability of WES services.The complex and fragmented reimbursement landscape presents a significant barrier to growth, particularly in the clinical diagnostics sector. Securing adequate payment for WES from public and private payers is challenging, as they often demand extensive evidence of clinical utility and cost-effectiveness before establishing positive coverage policies. In some regions, coverage remains inconsistent, making it difficult for providers to adopt WES as a standard tool. With chronic diseases on the rise—affecting as many as six in ten adults in some developed nations—the need for advanced diagnostics is clear, yet reimbursement hurdles delay broader access. Additionally, evolving regulatory environments, impose stringent requirements for clinical evidence and post-market surveillance, adding complexity and cost for manufacturers and laboratories.
Exclusive Customer Landscape
The whole exome sequencing market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the whole exome sequencing market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, whole exome sequencing market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Agilent Technologies Inc. - Key offerings in the market are centered on providing comprehensive, end-to-end whole exome sequencing solutions. This includes industry-leading target enrichment products and kits designed for the efficient capture of exonic regions prior to sequencing. Portfolios often feature complete workflows that encompass sample preparation, advanced sequencing platforms and the associated reagents, and integrated bioinformatics software for data analysis. Many offerings are structured as sample-to-insight solutions, delivering not just raw data but also actionable interpretations for both research and clinical applications. These solutions are increasingly optimized for high throughput, fast turnaround times, and compatibility with automated laboratory systems to meet the growing demand for scalable genomic analysis.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Agilent Technologies Inc.
- Ambry Genetics
- Azenta US Inc.
- BGI Genomics Co. Ltd.
- Bio Rad Laboratories Inc.
- CD Genomics
- Eurofins Scientific SE
- F. Hoffmann La Roche Ltd.
- GeneDx LLC
- Illumina Inc.
- Laboratory Corp. of America Holdings
- Macrogen Inc.
- Novogene Co. Ltd.
- Oxford Nanopore Technologies plc
- Pacific Biosciences of California Inc.
- PerkinElmer U.S. LLC
- ProPhase Labs, Inc.
- Psomagen Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Whole Exome Sequencing Market
In April 2024, Rady Childrens Institute for Genomic Medicine announced a new strategic partnership to significantly broaden access to its rapid genomic sequencing services for critically ill newborns.In April 2024, Precision Health Research, Singapore (PRECISE), the central entity executing the National Precision Medicine program, announced the launch of multiple clinical implementation pilots to test the utility and cost-effectiveness of using genomic data, including WES.In March 2024, Fabric Genomics announced significant enhancements to its artificial intelligence engine, specifically designed to accelerate variant interpretation and increase the diagnostic yield from genomic tests like WES.In February 2024, the US National Institutes of Health's All of Us Research Program announced a massive data release to its research community, which included nearly 250,000 whole genome sequences, stimulating the broader sequencing market.
Research Analyst Overview
The global whole exome sequencing market is characterized by the continuous evolution of next generation sequencing platforms. This progression influences the entire workflow, from exonic dna enrichment using exome enrichment kits and exome capture kits to streamlined library preparation kits. A diversity of methods, including sequencing by synthesis and ion semiconductor sequencing, supports both established short read sequencing and emerging long read sequencing technologies. This dynamic enables high-throughput sequencing at scale, moving beyond targeted gene panels to provide a more comprehensive view compared to whole genome sequencing. The adaptation of these techniques is critical for identifying a spectrum of genetic variations, from single nucleotide variants to complex structural variants and copy number variations, which is fundamental to the market's development.Following data generation, the focus shifts to the bioinformatics pipeline for processing raw sequence data and conducting variant interpretation. The integration of artificial intelligence in genomics and sophisticated machine learning algorithms is improving clinical variant interpretation, especially in resolving variants of uncertain significance and identifying disease causing mutations like somatic mutations. This analytical enhancement directly impacts the diagnostic yield for rare genetic diseases and refines targeted therapy selection, with industry expectations suggesting a market expansion of approximately 14% annually. The market's evolution is demonstrated by its role in pharmacogenomics and population health initiatives. Moreover, insights from germline sequencing inform next generation biotherapeutics, including gene therapy and cell therapy, while advancements in cloud computing in genomics and genomic data infrastructure support the data demands from machine learning clinical trials and the creation of digital therapeutics.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Whole Exome Sequencing Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
299
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 21.1%
|
|
Market growth 2024-2029
|
USD 3.7 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
20.6%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, The Netherlands, Spain, Russia, China, Japan, India, South Korea, Indonesia, Thailand, Singapore, Australia, Brazil, UAE, South Africa, Saudi Arabia, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Whole Exome Sequencing Market Research and Growth Report?
- CAGR of the Whole Exome Sequencing industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the whole exome sequencing market growth of industry companies
We can help! Our analysts can customize this whole exome sequencing market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Whole Exome Sequencing Market 2019 - 2023
- Historic Market Size - Data Table on Global Whole Exome Sequencing Market 2019 - 2023 ($ billion)
- 5.2 Product segment analysis 2019 - 2023
- Historic Market Size - Product Segment 2019 - 2023 ($ billion)
- 5.3 Technology segment analysis 2019 - 2023
- Historic Market Size - Technology Segment 2019 - 2023 ($ billion)
- 5.4 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Five Forces Analysis
- 6 Five Forces Analysis
- 6.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 6.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 6.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 6.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 6.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 6.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 6.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
7 Market Segmentation by Product
- 7 Market Segmentation by Product
- 7.1 Market segments
- Chart on Product - Market share 2024-2029 (%)
- Data Table on Product - Market share 2024-2029 (%)
- 7.2 Comparison by Product
- Chart on Comparison by Product
- Data Table on Comparison by Product
- 7.3 Consumables - Market size and forecast 2024-2029
- Chart on Consumables - Market size and forecast 2024-2029 ($ billion)
- Data Table on Consumables - Market size and forecast 2024-2029 ($ billion)
- Chart on Consumables - Year-over-year growth 2024-2029 (%)
- Data Table on Consumables - Year-over-year growth 2024-2029 (%)
- 7.4 Services - Market size and forecast 2024-2029
- Chart on Services - Market size and forecast 2024-2029 ($ billion)
- Data Table on Services - Market size and forecast 2024-2029 ($ billion)
- Chart on Services - Year-over-year growth 2024-2029 (%)
- Data Table on Services - Year-over-year growth 2024-2029 (%)
- 7.5 Instruments - Market size and forecast 2024-2029
- Chart on Instruments - Market size and forecast 2024-2029 ($ billion)
- Data Table on Instruments - Market size and forecast 2024-2029 ($ billion)
- Chart on Instruments - Year-over-year growth 2024-2029 (%)
- Data Table on Instruments - Year-over-year growth 2024-2029 (%)
- 7.6 Market opportunity by Product
- Market opportunity by Product ($ billion)
- Data Table on Market opportunity by Product ($ billion)
8 Market Segmentation by Technology
- 8 Market Segmentation by Technology
- 8.1 Market segments
- Chart on Technology - Market share 2024-2029 (%)
- Data Table on Technology - Market share 2024-2029 (%)
- 8.2 Comparison by Technology
- Chart on Comparison by Technology
- Data Table on Comparison by Technology
- 8.3 Sequencing by synthesis - Market size and forecast 2024-2029
- Chart on Sequencing by synthesis - Market size and forecast 2024-2029 ($ billion)
- Data Table on Sequencing by synthesis - Market size and forecast 2024-2029 ($ billion)
- Chart on Sequencing by synthesis - Year-over-year growth 2024-2029 (%)
- Data Table on Sequencing by synthesis - Year-over-year growth 2024-2029 (%)
- 8.4 ION semiconductor sequencing - Market size and forecast 2024-2029
- Chart on ION semiconductor sequencing - Market size and forecast 2024-2029 ($ billion)
- Data Table on ION semiconductor sequencing - Market size and forecast 2024-2029 ($ billion)
- Chart on ION semiconductor sequencing - Year-over-year growth 2024-2029 (%)
- Data Table on ION semiconductor sequencing - Year-over-year growth 2024-2029 (%)
- 8.5 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 8.6 Market opportunity by Technology
- Market opportunity by Technology ($ billion)
- Data Table on Market opportunity by Technology ($ billion)
9 Market Segmentation by Application
- 9 Market Segmentation by Application
- 9.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 9.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 9.3 Drug discovery and development - Market size and forecast 2024-2029
- Chart on Drug discovery and development - Market size and forecast 2024-2029 ($ billion)
- Data Table on Drug discovery and development - Market size and forecast 2024-2029 ($ billion)
- Chart on Drug discovery and development - Year-over-year growth 2024-2029 (%)
- Data Table on Drug discovery and development - Year-over-year growth 2024-2029 (%)
- 9.4 Diagnostics - Market size and forecast 2024-2029
- Chart on Diagnostics - Market size and forecast 2024-2029 ($ billion)
- Data Table on Diagnostics - Market size and forecast 2024-2029 ($ billion)
- Chart on Diagnostics - Year-over-year growth 2024-2029 (%)
- Data Table on Diagnostics - Year-over-year growth 2024-2029 (%)
- 9.5 Personalized medicine - Market size and forecast 2024-2029
- Chart on Personalized medicine - Market size and forecast 2024-2029 ($ billion)
- Data Table on Personalized medicine - Market size and forecast 2024-2029 ($ billion)
- Chart on Personalized medicine - Year-over-year growth 2024-2029 (%)
- Data Table on Personalized medicine - Year-over-year growth 2024-2029 (%)
- 9.6 Prenatal and neonatal screening - Market size and forecast 2024-2029
- Chart on Prenatal and neonatal screening - Market size and forecast 2024-2029 ($ billion)
- Data Table on Prenatal and neonatal screening - Market size and forecast 2024-2029 ($ billion)
- Chart on Prenatal and neonatal screening - Year-over-year growth 2024-2029 (%)
- Data Table on Prenatal and neonatal screening - Year-over-year growth 2024-2029 (%)
- 9.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 9.8 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
10 Customer Landscape
- 10 Customer Landscape
- 10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape
- 11 Geographic Landscape
- 11.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 11.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 11.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 11.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 11.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 11.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 11.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 11.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 11.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 11.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 11.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 11.4.5 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 11.4.6 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 11.4.7 Russia - Market size and forecast 2024-2029
- Chart on Russia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Russia - Market size and forecast 2024-2029 ($ billion)
- Chart on Russia - Year-over-year growth 2024-2029 (%)
- Data Table on Russia - Year-over-year growth 2024-2029 (%)
- 11.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 11.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 11.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 11.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 11.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 11.5.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 11.5.6 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 11.5.7 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 11.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 11.6.1 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 11.6.2 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 11.6.3 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 11.6.4 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 11.6.5 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 11.6.6 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 11.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
12 Drivers, Challenges, and Opportunity
- 12 Drivers, Challenges, and Opportunity
- 12.1 Market drivers
- Technological advancements and precipitous decline in sequencing costs
- Expanding clinical utility and integration into standard diagnostic workflows
- Proliferation of large scale government and private precision medicine initiatives
- 12.2 Market challenges
- Bioinformatics bottleneck and complexity of data interpretation
- Inconsistent reimbursement policies and evolving regulatory landscapes
- Ethical, legal, and social implications (ELSI) surrounding data privacy and consent
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 12.4 Market opportunities
- Integration of artificial intelligence and machine learning for accelerated variant interpretation
- Proliferation of whole exome sequencing in population health initiatives and mainstream clinical practice
- Ascendancy of long read sequencing technologies for enhanced exome characterization
13 Competitive Landscape
- 13 Competitive Landscape
- 13.1 Overview
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14 Competitive Analysis
- 14.1 Companies profiled
- 14.2 Company ranking index
- 14.3 Market positioning of companies
- Matrix on companies position and classification
- 14.4 Agilent Technologies Inc.
- Agilent Technologies Inc. - Overview
- Agilent Technologies Inc. - Business segments
- Agilent Technologies Inc. - Key news
- Agilent Technologies Inc. - Key offerings
- Agilent Technologies Inc. - Segment focus
- SWOT
- 14.5 Ambry Genetics
- Ambry Genetics - Overview
- Ambry Genetics - Product / Service
- Ambry Genetics - Key offerings
- SWOT
- 14.6 Azenta US Inc.
- Azenta US Inc. - Overview
- Azenta US Inc. - Business segments
- Azenta US Inc. - Key news
- Azenta US Inc. - Key offerings
- Azenta US Inc. - Segment focus
- SWOT
- 14.7 BGI Genomics Co. Ltd.
- BGI Genomics Co. Ltd. - Overview
- BGI Genomics Co. Ltd. - Product / Service
- BGI Genomics Co. Ltd. - Key offerings
- SWOT
- 14.8 CD Genomics
- CD Genomics - Overview
- CD Genomics - Product / Service
- CD Genomics - Key offerings
- SWOT
- 14.9 Eurofins Scientific SE
- Eurofins Scientific SE - Overview
- Eurofins Scientific SE - Business segments
- Eurofins Scientific SE - Key offerings
- Eurofins Scientific SE - Segment focus
- SWOT
- 14.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 14.11 Illumina Inc.
- Illumina Inc. - Overview
- Illumina Inc. - Business segments
- Illumina Inc. - Key news
- Illumina Inc. - Key offerings
- Illumina Inc. - Segment focus
- SWOT
- 14.12 Macrogen Inc.
- Macrogen Inc. - Overview
- Macrogen Inc. - Product / Service
- Macrogen Inc. - Key offerings
- SWOT
- 14.13 Novogene Co. Ltd.
- Novogene Co. Ltd. - Overview
- Novogene Co. Ltd. - Product / Service
- Novogene Co. Ltd. - Key offerings
- SWOT
- 14.14 Oxford Nanopore Technologies plc
- Oxford Nanopore Technologies plc - Overview
- Oxford Nanopore Technologies plc - Product / Service
- Oxford Nanopore Technologies plc - Key offerings
- SWOT
- 14.15 Pacific Biosciences of California Inc.
- Pacific Biosciences of California Inc. - Overview
- Pacific Biosciences of California Inc. - Product / Service
- Pacific Biosciences of California Inc. - Key news
- Pacific Biosciences of California Inc. - Key offerings
- SWOT
- 14.16 Psomagen Inc.
- Psomagen Inc. - Overview
- Psomagen Inc. - Product / Service
- Psomagen Inc. - Key offerings
- SWOT
- 14.17 QIAGEN N.V.
- QIAGEN N.V. - Overview
- QIAGEN N.V. - Product / Service
- QIAGEN N.V. - Key news
- QIAGEN N.V. - Key offerings
- SWOT
- 14.18 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
15 Appendix
- 15 Appendix
- 15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- 15.5 Data procurement
- 15.6 Data validation
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.8 Data synthesis
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
